60 results
Page 2 of 3
8-K
EX-99.1
7m2 igq4dg
12 Jul 22
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
5:33pm
8-K
EX-99.1
lqjutz7mzezah tx
6 May 22
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
5:15pm
8-K
EX-99.1
cdhxr1sqzy h3u2
20 Apr 22
Regulation FD Disclosure
5:15pm
8-K
EX-99.1
pvkzg21349tly7qhk
10 Jan 22
Regulation FD Disclosure
9:02am
8-K
EX-99.1
feen9p4vgzqx
21 Oct 21
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
4:20pm
8-K
EX-99.1
a2at8r ueof1pns5
24 Sep 21
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
4:01pm
8-K
EX-99.1
agtaox
1 Sep 21
Odyssey Group International Approved to Start Human Trial to Treat Concussion
4:15pm
8-K
EX-99.1
c0evkxih5te
6 Aug 21
Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial
4:24pm
DEF 14A
mwapc
6 Aug 21
Definitive proxy
4:02pm
PRER14A
8pgelnp 9waebpm5jx
28 May 21
Preliminary revised proxy
5:09pm
PRE 14A
hh2dhlfy9q 40
7 May 21
Preliminary proxy
5:27pm
S-3
4ltn6jnxqst
17 Mar 21
Shelf registration
4:30pm
8-K
EX-99.1
wgntaixyns1hpx6g2v
2 Mar 21
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug
8:45am
8-K
EX-10.1
0s0kagr6xk
26 Jan 21
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.2
5b2299xr7klm06np0ln
26 Jan 21
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-99.6
zmxi6dkczr08uvg1hv
11 Jan 21
Entry into a Material Definitive Agreement
3:19pm
8-K
EX-10.5
x80gsekdy4f3 mpu2
8 Jan 21
Entry into a Material Definitive Agreement
5:21pm
424B3
5yegmz0u
8 Dec 20
Prospectus supplement
3:15pm